Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with Metastatic Clear Cell Renal Cell Carcinoma

Gene signatures and tumour microenvironments were identified that associate with nivolumab outcomes
21 Sep 2020
Renal Cell Cancer

The predictive value provided by T effector (Teff) and angiogenesis (Angio) signatures was augmented by Kidney Immune Classification (KIC) of tumour microenvironments, which were also indicative of outcome following nivolumab treatment of patients with metastatic clear cell renal cell carcinoma (ccRCC). These findings were presented by Maxime Meylan of the Inflammation, complement and cancer, Centre de Recherche des Cordeliers in Paris, France at the ESMO Virtual Congress 2020.

Meylan and colleagues were prompted by a report from the NIVOREN GETUG-AFU 26 study that nivolumab provided safety and efficacy for patients with metastatic ccRCC in a real world setting to undertake this Kidney Immune Classification (KIC) project. Their study determined gene expression signatures and tumour microenvironments to assess their association with patient outcome following nivolumab with the aim of identifying biomarkers for nivolumab activity.

The translational cohort of Nivoren comprised 324 ccRCC FFPE samples; of these 184 were profiled by 3’ RNA sequencing and split in a Discovery (n=79) and Validation (n=105) cohorts.

Using the procedure outlined in the IMmotion 150 RCC study, the investigators assessed the impact of Teff and Angio signatures on patient outcome, based on median mRNA expression values. Their next step was to perform an unsupervised analysis using the Microenvironment Cell Populations- (MCP-) Counter to classify tumours according to their infiltration by 8 immune (I; fibroblasts) and 2 stromal (S; endothelial) cell populations, with the aim of characterising the tumour microenvironment.

The study outcomes included response rate (RR; best response determined by complete or partial response) and PFS.

KIC defined tumour microenvironments that were linked to patient outcomes after nivolumab treatment

Although the Angio and Teff signatures taken separately were not predictive of outcomes following nivolumab, the combination of these two signatures was highly informative.

Combined Angio and Teff signatures applied together in the analysis revealed that the most aggressive tumours, Teff-high/Angio-low and Teff-low/Angio-low, were significantly associated with RR and PFS in the Discovery cohort. Favourable outcome was indicated by a Teff-high/Angio-low signature, which associated with a RR of 47% (p = 0.01) and median PFS of 10.1 months (95% confidence interval [CI] 2.7- not estimable [NE]; p = 0.0005), whereas Teff-low/Angio-low associated with poorer RR of 5% (p = 0.01) and median PFS of just 2.6 months (95% CI 2.1-2.8; p = 0.0005).

Unsupervised classification identified 5 KIC subtypes, which were designated A to E. KIC C+E tumours had high levels of CD8+ cells, but low numbers of stromal cells (CD8-high/S-low) and were associated with Improved RR and PFS, as compared to  KIC A tumours (I-low/S-low), KIC B (I-low/S-high), and KIC C tumours (I-high/S-high).

Evaluation of the KIC classification identified tumour microenvironments that were associated with nivolumab outcomes in the Discovery cohort. Specifically, KIC C-E associated with a 48% RR (p = 0.005) and median PFS of 11.4 months (95% CI 2.4-NE; p = 0.03) and KIC A-B-D- associated with a 15% RR (p = 0.005) and median PFS of just 2.8 months (95% CI, 2.7-4.2; p = 0.03). In the Validation cohort, the KIC classification was also associated with nivolumab outcome, the KIC C-E displayed 36% RR (p = 0.0438) and the KIC A-B-D 11% RR (p = 0.0438).


Teff-high/Angio-low and KIC CE Immune-high/Stromal-low associated with favourable ORR on nivolumab in the Discovery cohort (n=79); ORR: Objective response rate. KIC: Kidney Immune Classification. Teff: T effector signature. Angio: Angiogenesis signature.

© Maxime Meylan.

According to principal component analysis, a similar contribution of KIC stromal cells and the Angio signatures was apparent in tumours associated with the worst outcomes.


The authors stated that this is the first report from a prospective trial that Immune high/angiogenesis and stromal low signatures may be predictive of nivolumab efficacy in patients metastatic ccRCC patients.

Their findings further suggest that KIC provides a first step in unravelling the deleterious clinical impact of potential immunosuppression that is contributed by neutrophils, fibroblasts, and endothelial cells in the tumour microenvironment.

Funding was reported from the Institut National du Cancer and Bristol-Myers Squibb.


700O – Meylan M, Beuselinck B, Dalban C, et al. Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to Nivolumab (N). ESMO Virtual Congress 2020.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.